AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATAI

Angermayer Christian sold (to issuer) 55,197,516 shares of ATAI (indirect holdings)

Angermayer Christian sold (to issuer) 55,197,516 indirectly-held shares of AtaiBeckley Inc. (ATAI) across 2 trades on 2026-09-11. Filed jointly with Apeiron Investment Group Ltd. (10% owner).

Original reporting
SEC EDGAR · Angermayer Christian, Apeiron Investment Group Ltd.
Published Sep 11, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATAI
Bearish
medium confidence
Mentioned
$ATAI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAIBearishMed
01

Why it matters

The sale removes a major insider from the shareholder base, potentially affecting governance perception.

02

Market read

Primary insider sell event; may influence short-term trading sentiment.

03

What to watch

No price disclosed; market may have already priced the sale.

Relevance 6/10Novelty 6/10Timing: 2026-09-11 filing

Background

Form 4 filings disclose insider transactions; a director selling a full stake is noteworthy.

Company-level read

Ticker impact

$ATAIBearishMedium confidence
Context

Director and 10% owner Christian Angermayer sold all 55,197,516 shares in a Form 4 filing.

Expected impact

Potential short-term downside as market absorbs the sell-off.

Evidence & confidence

55M shares represent a significant stake; the complete exit suggests material insider sentiment.

Market effects

Sector

May raise concerns for biotech sector investors about insider confidence.

Regional

Limited to US biotech market; no broader regional effect.

Global

Minimal global impact beyond ATAI shareholders.

Counterpoint

What could challenge this read

Insider sell could be a routine liquidity move, not necessarily a negative signal.

Key entities

  • Director
    Christian Angermayer

    10% owner of ATAI who sold all holdings.

  • Company
    Atai Beckley Inc.

    Biotech firm listed on NASDAQ under ticker ATAI.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATAI insider trading history →

Related articles

SEP 11
$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

vocal.media3 min
SEP 11
$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

blockonomi.com2 min
SEP 11
$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

citybiz.co2 min
SEP 11
$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.

minichart.com.sg2 min